Breakdown | |||||
TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | Total Revenue | ||||
6.36M | 6.93M | 7.75M | 7.02M | 5.11M | 2.84M | Gross Profit |
5.09M | 5.64M | 1.43M | 4.98M | 3.44M | 2.04M | EBIT |
-4.14M | -4.01M | -8.83M | -9.69M | -5.00M | -4.86M | EBITDA |
-3.94M | -3.55M | -7.85M | -11.37M | -4.53M | -4.90M | Net Income Common Stockholders |
-4.71M | -4.30M | -8.52M | -10.74M | -4.57M | -13.59M |
Balance Sheet | Cash, Cash Equivalents and Short-Term Investments | ||||
3.13M | 437.60K | 511.40K | 2.64M | 7.75M | 17.51M | Total Assets |
11.18M | 8.62M | 4.52M | 11.91M | 17.77M | 22.52M | Total Debt |
67.67K | 1.78M | 365.35K | 2.22M | 264.16K | 730.47K | Net Debt |
-3.07M | 1.34M | -146.05K | -414.09K | -7.49M | -16.26M | Total Liabilities |
3.66M | 4.84M | 3.45M | 4.85M | 2.19M | 2.19M | Stockholders Equity |
7.53M | 3.77M | 1.06M | 7.06M | 15.58M | 20.34M |
Cash Flow | Free Cash Flow | ||||
-4.06M | -2.93M | -3.79M | -6.31M | -9.02M | -4.99M | Operating Cash Flow |
-4.05M | -2.91M | -3.79M | -6.23M | -8.98M | -4.95M | Investing Cash Flow |
-15.75K | -13.05K | -1.00K | -696.62K | -42.02K | -2.23M | Financing Cash Flow |
6.41M | 2.83M | 1.43M | 1.90M | -218.60K | 24.09M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
66 Neutral | $4.51B | 12.29 | 5.40% | 248.53% | 4.14% | -12.41% | |
51 Neutral | $3.24M | ― | -362.03% | ― | 23.07% | 50.04% | |
49 Neutral | $4.98M | ― | -116.82% | ― | -7.25% | 80.12% | |
37 Underperform | $3.55M | ― | -3420.59% | ― | -11.38% | -9.63% | |
35 Underperform | $19.10M | ― | 220.90% | ― | -92.71% | 39.07% | |
$4.04M | ― | -170.63% | ― | ― | ― | ||
$5.68M | ― | -352.74% | ― | ― | ― |
On May 9, 2025, BIO-key International received a notice from Nasdaq indicating that its stock price had fallen below the $1.00 minimum bid requirement for 30 consecutive business days, risking delisting. The company has until November 5, 2025, to regain compliance, with potential for an additional 180-day extension if necessary. In Q1 2025, BIO-key reported a revenue of $1.6 million, a decrease from the previous year, but noted improvements in cash position and a reduction in operating expenses. The company is optimistic about future growth, driven by increased adoption of its biometric solutions and strategic partnerships, despite fluctuations in quarterly financial performance.
The most recent analyst rating on (BKYI) stock is a Buy with a $3.00 price target. To see the full list of analyst forecasts on BIO-key International stock, see the BKYI Stock Forecast page.
On April 17, 2025, BIO-key International received a notice from Nasdaq for non-compliance with a listing rule due to a delay in filing its Annual Report for 2024. The company resolved the issue by filing the report on April 23, 2025, and regained compliance with Nasdaq’s listing requirements by April 24, 2025, ensuring no impact on its stock trading.